1 / 6

Chronic Obstructive Pulmonary Disease Pipeline to Receive More R&D Investments in the Future

The study analyzed that the chronic obstructive pulmonary disease pipeline comprises 65 drug candidates in different stages of development. Chronic obstructive pulmonary disease is a broad term used for progression of various other diseases that affect the lungs such as, emphysema, chronic bronchitis.

NidhiNehani
Download Presentation

Chronic Obstructive Pulmonary Disease Pipeline to Receive More R&D Investments in the Future

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Chronic Obstructive Pulmonary Disease Pipeline to Witness Many Technological Advancements in the Coming Years

  2. Chronic Obstructive Pulmonary Disease (COPD) According to a new research report “Chronic Obstructive Pulmonary Disease Therapeutics Pipeline Analysis, 2017 - Clinical Trials & Results, Patent, Designation, Collaboration, and Other Developments” published by P&S Market Research, Chronic obstructive pulmonary disease currently exhibits a pipeline with 65 drug candidates. Browse Report Overview at: https://www.psmarketresearch.com/market-analysis/copd-therapeutics-pipeline-analysis Chronic obstructive pulmonary disease pipeline in 2017 The study analyzed that the chronic obstructive pulmonary disease pipeline comprises 65 drug candidates in different stages of development. Chronic obstructive pulmonary disease is a broad term used for progression of various other diseases that affect the lungs such as, emphysema, chronic bronchitis.

  3. Chronic Obstructive Pulmonary Disease (COPD) Insights on pipeline segments As per the findings of the research, most of the drug candidates of chronic obstructive pulmonary disease pipeline are being developed to be administered by inhalation route. Human combinatorial antibody library (HuCAL) technology platform for Chronic Obstructive Pulmonary Disease drug development MorphoSys AG is using human combinatorial antibody library (HuCAL) technology platform for the development of their drug candidates in chronic obstructive pulmonary disease. The technology is used for the in vitro generation of highly specific and fully human antibodies.

  4. Chronic Obstructive Pulmonary Disease (COPD) Major companies collaborate for the development of Chronic Obstructive Pulmonary Disease Therapeutics Pipeline The research found that various companies have collaborated for the development of chronic obstructive pulmonary disease therapeutics pipeline. In March 2017, Kyowa Hakko Kirin Co., Ltd. collaborated with AstraZeneca plc, had given the exclusive rights to AstraZeneca plc for benralizumab in Asia. Some of the key players developing drugs for the treatment of chronic obstructive pulmonary disease include AstraZeneca plc, GlaxoSmithKline plc, Adamis Pharmaceuticals Corporation and others.

  5. Chronic Obstructive Pulmonary Disease (COPD) Download report sample at: https://www.psmarketresearch.com/market-analysis/copd-therapeutics-pipeline-analysis/report-sample

  6. GET IN TOUCH THANK YOU! For information regarding permissions and other queries Kindly write to: US/Canada Toll-Free: 1-888-778-7886

More Related